From the Departments of Nuclear Medicine.
Radiology.
Clin Nucl Med. 2021 Feb 1;46(2):e106-e108. doi: 10.1097/RLU.0000000000003336.
Triple negative breast cancer (TNBC) is characterized by poor prognosis and limited response to standard treatments. Although 18F-FDG PET/CT is frequently used in staging and restaging, in some cases, it may be insufficient considering tumor heterogeneity. Prostate-specific membrane antigen (PSMA) has been reported to be overexpressed in many types of cancer due to tumor-associated neovascularization. 68Ga-PSMA-11 PET/CT can be used to demonstrate radionuclide therapy option as well as detection of primary tumor and recurrence in TNBC. We present a 47-year-old woman with TNBC having recurrent brain metastasis with avid PSMA receptor activity versus low FDG uptake.
三阴性乳腺癌（TNBC）的特点是预后不良，对标准治疗的反应有限。尽管 18F-FDG PET/CT 常用于分期和再分期，但在某些情况下，考虑到肿瘤异质性，它可能不够充分。由于肿瘤相关新生血管形成，前列腺特异性膜抗原（PSMA）已被报道在许多类型的癌症中过度表达。68Ga-PSMA-11 PET/CT 可用于显示放射性核素治疗选择以及 TNBC 中原发性肿瘤和复发的检测。我们介绍了一位 47 岁的女性 TNBC 患者，她患有复发性脑转移，PSMA 受体活性高，而 FDG 摄取低。
